Loading
EGFRvIII is a mutant, tumour-only version of the EGFR receptor found in about a third of glioblastomas. It is an ideal-looking target, yet every drug against it has failed so far.
In-frame deletion of exons 2-7 creating a constitutively active receptor with a tumour-specific junctional epitope. Targeted by rindopepimut (ACT IV negative), EGFRvIII CAR-T (antigen loss), bispecifics (AMG 596), and ADCs (depatuxizumab mafodotin, INTELLANCE-1 negative). Expression is heterogeneous and frequently lost at recurrence.
In plain words · A growth receptor that is mutated in some lung cancers and overproduced in others; the first great success of targeted pills.
Showing the target this term concerns: EGFR.
Shares Rindopepimut, ACT IV.
Shares CAR-T for glioma (IL13Rα2, GD2, EGFRvIII, multi-target), The brain: barrier and sanctuary, Glioma & glioblastoma.
Shares CAR-T for glioma (IL13Rα2, GD2, EGFRvIII, multi-target), The brain: barrier and sanctuary, Glioma & glioblastoma.
Shares Drug resistance (primary and acquired), Receptor tyrosine kinase activation, EGFR.
Shares Drug resistance (primary and acquired), Receptor tyrosine kinase activation, EGFR.
Shares Drug resistance (primary and acquired), Receptor tyrosine kinase activation, EGFR.
Shares The brain: barrier and sanctuary, Glioma & glioblastoma.
Shares Drug resistance (primary and acquired), Receptor tyrosine kinase activation, EGFR.